The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The "INRange" RCT

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02376803

Recruitment Status : Completed

First Posted : March 3, 2015

Last Update Posted : May 4, 2018

Sponsor:

Collaborator:

Vancouver Coastal Health Research Institute

Information provided by (Responsible Party):

Scott Garrison, University of Alberta

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	September 30, 2016
Actual Study Completion Date :	April 27, 2018

Publications:

Hirsh J, Fuster V, Ansell J, Halperin JL; American Heart Association; American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003 Apr 1;107(12):1692-711. Review.

van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006 May;129(5):1155-66. Review.

Hylek EM. Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. J Thromb Thrombolysis. 2013 Apr;35(3):333-5. doi: 10.1007/s11239-013-0900-5. Review.

UpToDate. Antithrombotic therapy to prevent embolization in atrial fibrillation. 2014; http://www.uptodate.com. Accessed June 6, 2014.

Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med. 2004 May 15;116(10):651-6.

Olson RE. The function and metabolism of vitamin K. Annu Rev Nutr. 1984;4:281-337. Review.

Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1992 Aug;1(2):113-9.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Heran BS, Allan GM, Green L, Korownyk C, Kolber M, Olivier N, Flesher M, Garrison S. Effect of medication timing on anticoagulation stability in users of warfarin (the INRange RCT): study protocol for a randomized controlled trial. Trials. 2016 Aug 4;17(1):391. doi: 10.1186/s13063-016-1516-9.

To Top